Vitti Long Haul

About Vitti Long Haul

Vitti Long Haul is committed to improving the lives of people affected by the lasting effects of COVID-19 through the development of innovative regenerative therapies. Focused on pulmonary fibrosis and persistent long-haul symptoms, our investigational treatments, VL-PX10 and VL-P22, are developed using mesenchymal stem cells, exosomes, and biomaterials and are currently in Phase 2 human clinical trials. For patients who are unable to participate in a clinical trial, our physician-led Expanded Access Program offers an additional pathway to care. Guided by FDA standards and grounded in years of scientific research, we continue to advance safe, effective, and promising treatment options for patients and healthcare providers alike.